Cisplatin and carboplatin have dominated the drug therapy of ovarian cancer and other
gynecologic malignancies during the past three decades. This review, based on a recent …

Encapsulation of doxorubicin in polyethylene glycol-coated liposomes (Doxil/Caelyx [PLD]),
was developed to enhance the safety and efficacy of conventional doxorubicin. The …

Purpose Convincing data support the link between inflammation and ovarian cancer. Tumor
necrosis factor-alpha (TNF-α), a major mediator of inflammation, is chronically produced in …

Peritoneal dissemination of ovarian cancer (OvCa) arises from the surface of the
peritoneum, covered by monolayer of mesothelial cells (MCs). Given that both OvCa cells …

The need for effective, well-tolerated, and convenient therapies for patients with advanced
ovarian cancer has led researchers to continually refine chemotherapeutic regimens to …

Ovarian cancer is the most lethal gynecological malignancy, characterized by a high rate of
chemoresistance. Current treatment strategies for ovarian cancer focus on novel drug …

OBJECTIVE: CircRNAs have been recently identified as important regulators in tumors
biological functions. However, the clinical significance of circHIPK3 in epithelial ovarian …

Resistance to cisplatin (CDDP) in ovarian cancer (OVCA) arises from the dysregulation of
tumor suppressors and survival signals. During genotoxic challenge, these factors can be …

The purpose of the current phase II single‐arm clinical trial was to evaluate whether
pretreatment with low‐dose cyclophosphamide improves immunogenicity of a p53‐synthetic …

Cancer is one of the most deadly diseases on the planet. Over the past decades, numerous
antineoplastic compounds have been discovered from natural resources such as medicinal …